๐ฐ Precision Surgery News
Page 2 - Precision Surgery News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Precision Surgery. Real-time updates on events, politics, business and more.
December 16, 2022
/PRNewswire/ -- On Target Laboratories, Inc., a privately-held biotechnology company developing intraoperative molecular imaging agents to target and...
August 23, 2022
Alume Biosciences announces first patient dosed in a trial of a peptide-dye conjugate that highlight nerves with fluorescence during surgery.
June 30, 2022
A grant from the National Cancer Institute will build on Pennโs pioneering role in the use of intraoperative imaging technology that makes it easier and safer to remove tumors on or in the lungsย
June 29, 2022
Building on Penn Medicine's years of research and use of imaging technology that illuminates tumor tissue-; helping clinicians more easily detect and remove it-; the Perelman School of Medicine at the University of Pennsylvania has received a five-year, $9 million research grant from the National Cancer Institute (NCI) to push the field forward, particularly for lung cancer patients.
May 23, 2022
Researchers at the Abramson Cancer Center at the University of Pennsylvania have developed a method to detect lung cancer at the cellular level in rea
February 1, 2022
/PRNewswire/ -- With healthcare costs continuing to rise, its no surprise that employers are eager to find new solutions to better serve their employees and...
February 1, 2022
PORTLAND, Ore., Feb. 1, 2022 /PRNewswire/ -- With healthcare costs continuing to rise, its no surprise that employers are eager to find new solut...
February 1, 2022
/PRNewswire/ -- With healthcare costs continuing to rise, its no surprise that employers are eager to find new solutions to better serve their employees and...
December 1, 2021
The U.S. Food and Drug Administration (FDA) today approved an imaging drug known as Cytalux (pafolacianine), which is attracted to ovarian cancer tissue and illuminates it when exposed to fluorescent light, allowing surgeons to more easily find and more precisely remove the cancer.
December 1, 2021
Cytalux (pafolacianince), a drug that binds to ovarian cancer tissue and glows when exposed to fluorescent light, has been approved by the U.S. Food and Drug Administration (FDA) to help surgeons detect ovarian tumors during surgical procedures in patients.